Navigation Links
ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development

LOS ANGELES, SINGAPORE, and TOKYO, July 28, 2014 /PRNewswire/ -- ImaginAb, Inc. today announced today announced that it has appointed Roger Crystal, MD as Vice President of Business Development. Dr. Crystal most recently served in the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences.

"Roger's experience in developing business strategy and partnerships in the precision medicine space will be extremely valuable as we continue to partner with biotechnology and pharmaceutical companies across the spectrum to extend the reach of ImaginAb's capabilities," said Dr. Christian Behrenbruch, co-founder and CEO of ImaginAb. "We are very pleased to welcome Roger to Los Angeles and look forward to his contributions as a member of the ImaginAb executive team."

Prior to joining ImaginAb, Dr. Crystal served on the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences where he was responsible for evaluating in vivo and in vitro molecular and IT technologies for acquisitions, licensing or partnering deals.  In this capacity he also managed pharmaceutical company engagements, out-licensing deals and commercialization partnerships for late stage molecular imaging agents including molecular imaging technologies. Dr. Crystal also has prior management consulting and corporate M&A experience from AT Kearney and Goldman Sachs.

"ImaginAb's proprietary antibody fragment technology has the potential to transform the way patients are staged and managed in cancer and immunology indications," commented Dr. Crystal. "I am enthusiastic to be joining ImaginAb, particularly at a time when the application of our products has the potential to further advance the tremendous progress being made in the immuno-oncology field."

Dr. Crystal holds degrees in Medicine and Physiology from the University of Birmingham and an MBA from the London Business School.  Dr. Crystal began his career as a surgeon at University College Hospital London and is a member of the Royal College of Surgeons of England specializing in otolaryngology, most recently at St Mary's Hospital (Imperial College), London.

About ImaginAb
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging.  The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare.

For more information, visit

SOURCE ImaginAb, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
2. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
3. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
4. Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
5. Pharmavite Appoints Timothy Toll Chief Customer Officer
6. Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer
7. BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors
8. PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board
9. Nonin Medical Appoints Ash Keswani Vice President of Marketing
10. InspireMD Appoints Dr. James Barry as Chief Operating Officer
11. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... ... 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively ... transitions to wipes with blur & drop shadow options. Utilize the controls in ... one clip to the next with TransPack's easily customizable styles. , TransPack ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... worldwide today released the results of a survey of educational needs for pharmacists ... found a growing global demand for high quality online and face-to-face education for ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
Breaking Medicine News(10 mins):